From Yahoo Finance: 2025-05-06 07:41:00

Zimmer Biomet adjusts 2025 earnings forecast to $7.90-$8.10 per share due to Trump administration tariffs, resulting in a stock drop of nearly 12%. The company anticipates a $60m-$80m drag on operating profit in 2025, with full-year operating margins expected to decrease by 100 to 150 basis points compared to 2024.

GE HealthCare warns of a potential $500m revenue loss in 2025 due to tariffs, leading to a downward adjustment in earnings per share to $3.90-$4.10 from previous estimates of $4.61-$4.75. Stryker also trims 2025 outlook, projecting a tariff revenue impact of around $200m and adjusting year-end guidance to $13.20-$13.45 per share.

Amidst the impact of tariffs, other medtech companies like Stryker are recalibrating their 2025 financial outlooks. With the shifting tariff landscape, companies are strategizing to mitigate potential revenue losses and adjust earnings expectations accordingly. Request a free demo for GlobalData’s Strategic Intelligence for real-time data and market-leading analysis.



Read more at Yahoo Finance: Zimmer Biomet flags $60m-$80m tariff impact on 2025 profits